Web Exclusives

Molecular testing of early-stage non–small-cell lung cancer is recommended after clinical trial results demonstrate osimertinib is effective for patients with EGFR-harboring tumors. Read More ›

A recent review of case reports of patients with non–small-cell lung cancer receiving immune checkpoint therapy finds neurologic adverse events are a rare but concerning side effect. Read More ›

Treatment with ribociclib and an aromatase inhibitor or fulvestrant for hormone receptor–positive, HER2-negative metastatic breast cancer did not increase the risk of thrombosis in the real-world setting. Read More ›

Palbociclib combined with letrozole is associated with improved outcomes for patients with hormone receptor–positive, HER2-negative metastatic breast cancer with lung or liver metastases in the first-line setting Read More ›

Study results reinforce that patient selection for abemaciclib treatment is critical to ensure adequate efficacy and safety. Read More ›

Recently released results using liquid biopsy shows KRAS G12C mutation in patients with NSCLC can be lost or acquired at progressive disease. Read More ›

Social listening can offer investigators valuable information about unmet patient needs and concerns regarding their cancer treatment and to direct future research. Read More ›

Researchers found a large underrepresentation gap among minority populations across major cancer types in clinical trials. Read More ›

Improved understanding of self-care behaviors in patients with cancer who take oral anticancer medications can help healthcare professionals support patient medication adherence. Read More ›

During active chemotherapy treatment, adopting an aerobic exercise program may reduce cancer-related fatigue. Read More ›